Physician profile
Timothy A Arling
NPI 1588930234
$5,279.05
in general payments reported to CMS, 2019-2025
42 companies · $661 in 2025
The $661 reported for 2025 was more than what 78% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $762 · 2020: $507 · 2021: $575 · 2022: $899 · 2023: $1,088 · 2024: $786 · 2025: $661.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,520 · Education: $15.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,520.36 |
| Education | $15.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $904.79 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Abbvie INC. | $637.66 | 2020-2025 | Ubrelvy, Qulipta, Vraylar |
| Pfizer INC. | $565.77 | 2019-2025 | |
| Lilly USA, LLC | $429.28 | 2019-2025 | Mounjaro, Zepbound, Emgality |
| Amgen INC. | $374.86 | 2019-2025 | Repatha, Otezla, Otezla |
| Allergan, INC. | $156.98 | 2020 | |
| Merck Sharp & Dohme LLC | $128.49 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $124.22 | 2022 | |
| Myriad Women'S Health, INC. | $121.48 | 2023 | Myrisk |
| Bausch Health US, LLC | $120.16 | 2023-2025 | Aplenzin, Wellbutrin |
| Novartis Pharmaceuticals Corporation | $115.61 | 2023-2025 | |
| Kaleo, INC. | $110.39 | 2019 | |
| Supernus Pharmaceuticals, INC. | $109.83 | 2022-2023 | Qelbree |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $108.72 | 2021-2025 | Xifaxan |
| Ironshore Pharmaceuticals INC. | $102.73 | 2019 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Arling listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.